| Code | Description | Claims | Beneficiaries | Total Paid |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
10,177 |
9,376 |
$1.43M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,072 |
5,405 |
$781K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
6,812 |
5,713 |
$696K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,716 |
3,193 |
$211K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,490 |
3,720 |
$206K |
| 71045 |
Radiologic examination, chest; single view |
2,233 |
1,856 |
$206K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,830 |
1,583 |
$195K |
| 71046 |
Radiologic examination, chest; 2 views |
835 |
744 |
$78K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
12,988 |
10,910 |
$59K |
| 80053 |
Comprehensive metabolic panel |
9,723 |
8,236 |
$56K |
| 36415 |
Collection of venous blood by venipuncture |
13,380 |
10,652 |
$50K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,531 |
1,274 |
$43K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
100 |
97 |
$37K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
476 |
433 |
$32K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
268 |
255 |
$32K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
414 |
394 |
$30K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
823 |
708 |
$29K |
| 80050 |
General health panel |
242 |
222 |
$29K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
145 |
138 |
$25K |
| 84484 |
|
3,654 |
2,567 |
$21K |
| 83605 |
|
3,408 |
2,590 |
$20K |
| 99201 |
|
131 |
122 |
$17K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
100 |
92 |
$12K |
| 83880 |
|
834 |
647 |
$12K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
382 |
357 |
$12K |
| 11721 |
|
232 |
160 |
$12K |
| 87503 |
|
414 |
394 |
$10K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
407 |
326 |
$9K |
| 11056 |
|
34 |
31 |
$8K |
| 80061 |
Lipid panel |
911 |
814 |
$7K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
85 |
77 |
$6K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,418 |
1,138 |
$6K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,725 |
1,383 |
$5K |
| 81003 |
|
3,021 |
2,328 |
$5K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
157 |
133 |
$5K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
813 |
745 |
$5K |
| 70450 |
Computed tomography, head or brain; without contrast material |
40 |
38 |
$5K |
| 81001 |
|
2,313 |
2,007 |
$5K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
296 |
267 |
$3K |
| 82800 |
|
481 |
403 |
$3K |
| 85379 |
|
407 |
321 |
$2K |
| 83690 |
|
505 |
436 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13 |
13 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
110 |
91 |
$2K |
| 87276 |
|
326 |
281 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
172 |
132 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
123 |
122 |
$2K |
| 87275 |
|
326 |
281 |
$2K |
| 82043 |
|
398 |
364 |
$2K |
| 82570 |
|
425 |
389 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
162 |
152 |
$1K |
| 81025 |
|
278 |
257 |
$1K |
| 85027 |
|
716 |
641 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
104 |
101 |
$1K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
17 |
14 |
$1K |
| 87040 |
|
318 |
142 |
$996.31 |
| 83735 |
|
316 |
269 |
$960.88 |
| 82803 |
|
119 |
70 |
$952.07 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
309 |
264 |
$757.70 |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
12 |
12 |
$729.44 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
63 |
62 |
$461.40 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
30 |
29 |
$385.25 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
20 |
12 |
$357.78 |
| 86803 |
|
40 |
38 |
$352.91 |
| 85610 |
|
158 |
112 |
$283.73 |
| 80076 |
|
28 |
27 |
$213.34 |
| 85730 |
|
53 |
39 |
$141.45 |
| G0127 |
Trimming of dystrophic nails, any number |
19 |
15 |
$130.80 |
| 82550 |
|
13 |
13 |
$27.73 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
47 |
24 |
$25.90 |
| 82948 |
|
16 |
13 |
$8.42 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
57 |
44 |
$0.00 |